These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6872420)

  • 21. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute nephrotoxicity caused by amphotericin B in the dog].
    Monteiro JL; Seguro AC; Rocha Ados S
    Rev Hosp Clin Fac Med Sao Paulo; 1993; 48(2):54-9. PubMed ID: 8235274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B removal by plasma exchange.
    Lew SQ
    J Clin Pharm Ther; 2009 Feb; 34(1):115-7. PubMed ID: 19125909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.
    Ferry N; Geoffroy J; Pozet N; Cuisinaud G; Benzoni D; Zech PY; Sassard J
    Br J Clin Pharmacol; 1988 Mar; 25(3):359-66. PubMed ID: 3358898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.
    Rudy AC; Knight PM; Brater DC; Hall SD
    J Pharmacol Exp Ther; 1995 Apr; 273(1):88-93. PubMed ID: 7714818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma.
    Schaefer F; Baumann G; Haffner D; Faunt LM; Johnson ML; Mercado M; Ritz E; Mehls O; Veldhuis JD
    J Clin Endocrinol Metab; 1996 Jan; 81(1):22-31. PubMed ID: 8550755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.
    St Peter JV; Brady ME; Foote EF; Dandekar KA; Smaldone L; Pykkonen JL; Keane WF; Halstenson CE
    Eur J Clin Pharmacol; 1993; 45(1):59-63. PubMed ID: 8405031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
    Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
    Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.
    Lecaillon JB; Dubois JP; Coppens H; Darragon T; Reumond G; Pozet N; Traeger J; Lambrey G
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):231-7. PubMed ID: 2253654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption of orally administered amphotericin B lozenges.
    Ching MS; Raymond K; Bury RW; Mashford ML; Morgan DJ
    Br J Clin Pharmacol; 1983 Jul; 16(1):106-8. PubMed ID: 6882617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.
    Ochs HR; Greenblatt DJ; Kaschell HJ; Klehr U; Divoll M; Abernethy DR
    Br J Clin Pharmacol; 1981 Dec; 12(6):829-32. PubMed ID: 7340884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1985 Jun; 37(6):697-700. PubMed ID: 3924464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein binding of bilirubin in plasma of anephric patients.
    Oie S; Lowenthal DT; Levy G
    J Dial; 1980; 4(2-3):91-100. PubMed ID: 7440847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacologic guide to the clinical use of amphotericin B.
    Bindschadler DD; Bennett JE
    J Infect Dis; 1969 Oct; 120(4):427-36. PubMed ID: 5394441
    [No Abstract]   [Full Text] [Related]  

  • 39. Amphotericin B pharmacokinetics in humans.
    Atkinson AJ; Bennett JE
    Antimicrob Agents Chemother; 1978 Feb; 13(2):271-6. PubMed ID: 646348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ex vivo plasma protein binding of theophylline in renal disease.
    Leopold D; Webb D; Buss DC; Fifield RA; Smith AP; Routledge PA
    Br J Clin Pharmacol; 1985 Jun; 19(6):823-5. PubMed ID: 4027123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.